Top

Supportive Care in Cancer

Published in:

01-04-2019 | Original Article

Relationship between skeletal muscle function, body composition, and weight loss in patients with advanced pancreatic and gastrointestinal cancers

Authors: P. Cresta Morgado, M. Daud, M. Carballido, G. Méndez, S. Iseas, V. Lobbe, G. De Simone, A. Navigante

Published in: Supportive Care in Cancer | Issue 4/2019

Abstract

Background

Muscle function and its correlation with body composition and weight loss have not been studied deeply in pancreas and gastrointestinal cancers. This research aims to determine the skeletal muscle function and its relationship with body compartments, significant weight loss, and performance status (ECOG) 0-2 in a population with advanced digestive cancers.

Methods

A cross-sectional study was designed to determine the relationship between muscular function, weight loss, and body composition. Patients with advanced digestive adenocarcinomas were evaluated. Muscle strength was examined by hand grip technique and body composition by bioimpedance analysis. Values of hemoglobin and albumin were measured in plasma.

Results

A sample of 81 patients was included. They had adenocarcinoma of stomach (n = 9), pancreas (n = 28), or colorectum (n = 44). With regard to skeletal muscle function, sub-maximal strength increased when percentage of weight loss decreased (p = 0.002) or when any of the following variables increased: skeletal muscle (p < 0.001), waist-hip ratio (p < 0.001), body surface area (p < 0.001), and body mass index (p = 0.001). According to multivariate analysis of these variables, only percentage of weight loss and skeletal muscle remained statistically significant. Endurance had no correlation with any of the variables. Higher weight loss was found in tumors of the upper tract (stomach and pancreas) in comparison with those of the lower tract (colorectal) (p = 0.005).

Conclusions

In advanced digestive cancer, sub-maximal strength correlated inversely with weight loss and directly with skeletal muscle such as in lung and head and neck cancers. On the other hand, endurance had no correlation with any of the variables considered.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66:7–30CrossRefPubMed

Libutti SK, Saltz LB, Wollet C, Levine RA (2015) Cancer of the colon. In: De Vita H, Rosenberg (eds) Cancer: principles & practice of oncology, vol 57, 10th edn. Wolters Kluwer, pp 768–812

Zheng P, Zhou Z (2015) Human cancer immunotherapy with PD-1/PD-L1 blockade. Biomark Cancer 7:15–18PubMedPubMedCentral

Matrisian L, Berlin J (2016) The past, present and future of pancreatic cancer clinical trials. Am Soc Clin Oncol Educ Book:e205-e215

Dry GK, Adjei A (2013) Understanding, recognizing, and managing toxicities of target anticancer therapies. CA Cancer J Clin 63:249–279CrossRef

Verger E, Salamero M, Comil C (1992) Can Karnofsky perfomance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer 28A:1328–1330CrossRefPubMed

Kilgour RD, Vigano A, Trutschingg B, Lucar E et al (2013) Handgrip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support Care Cancer 21:3261–3270CrossRefPubMed

Donohoe CL, Ryan AM, Reynolds JV (2011) Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract 2011:601434. https://doi.org/10.1155/2011/601434 CrossRefPubMedPubMedCentral

Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491–497CrossRefPubMed

10.

Dy S, Lorenz K, Naeim A, Homayoon S et al (2008) Evidence-based recommendations for cancer fatigue, depression and dyspnea. J Clin Oncol 26:3886–3895CrossRefPubMed

11.

Cerchietti L, Navigante A, Peluffo G, Diament M et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma. J Pain Symptom Manag 27:85–95CrossRef

12.

Hauser K, Rybicki L, Walsh D (2010) What’s in a name? Word descriptors of cancer-related fatigue. Palliat Med 24(7):724–730CrossRefPubMed

13.

Richardson A (1995) Fatigue in cancer patients: a review of the literature. Eur J Cancer Care 4:20–32CrossRef

14.

Luthy C, Cedraschi C, Pugliesi A, Di Silvestro K et al (2011) Patients ‘views about causes and preferences for the management of cancer-related fatigue-a case for non congruent with physicians? Support Care Cancer 19:363–370CrossRefPubMed

15.

Navigante A, Cresta Morgado P, Casbarien O, López Delgado N et al (2013) Relationship between weakness and phase angle in advanced cancer patients with fatigue. Support Care Cancer 21:1685–1690CrossRefPubMed

16.

Bautmans I, Gorus E, Njemini R, Mets T (2007) Handgrip performance in relation to self-perceived fatigue, physical functioning and circulating IL-6 in elderly persons without inflammation. BMC Geriatr 7:5CrossRefPubMedPubMedCentral

17.

Cresta Morgado P, Giorlando A, Castro M, Navigante A (2016) Relationship between weight loss and parameters of skeletal muscle function in patients with advanced cancer and fatigue. Support Care Cancer 24:3961–3966. https://doi.org/10.1007/s00520-016-3236-9 CrossRefPubMed

18.

Lenk K, Schuler G, Adams V (2010) Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 1:9–21. https://doi.org/10.1007/s13539-010-0007-1 CrossRefPubMedPubMedCentral

19.

Nedergaard A, Karsdal M, Sun S, Henriksen K (2013) Serological muscle loss biomarkers: an overview of current concepts and future possibilities. J Cachexia Sarcopenia Muscle 4:1–17. https://doi.org/10.1007/s13539-012-0086-2 CrossRefPubMed

20.

Ebner N, von Haeling S (2017) Highlights from the 9th cachexia conference. J Cachexia Sarcopenia Muscle 8:508–511. https://doi.org/10.1002/jcsm.12217 CrossRefPubMedPubMedCentral

21.

Clark B, Manini T (2012) What is dynapenia? Nutrition 28:495–503CrossRefPubMedPubMedCentral

22.

Lucia A, Ramírez M (2016) Muscling in cancer. N Engl J Med 375(9):892–894CrossRefPubMed

23.

Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE (2012) Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. BJC 107:931–936CrossRefPubMed

24.

Lieffers JR, Moutzakis M, Hall K, Mc Cargar L et al (2009) A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. Am J Clin Nutr 89:1173–1179CrossRefPubMedPubMedCentral

25.

Parsons H, Baracos V, Dhillon N, Hong D, Kurzrock R (2012) Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One 7(1):e29330: 1–7. https://doi.org/10.1371/journal.pone.0029330 CrossRefPubMedPubMedCentral

26.

Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler M et al (2008) Cachexia worsen prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 12:1193–1201CrossRefPubMed

27.

Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, Javle S, Shroff R, Varadhachary G, Wolff R, Vence L, Maitra A, Cleeland C, Wang XS (2017) A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer 25(6):1809–1817CrossRefPubMed

28.

Fisher D, Tish KM, Durivage H, Beaulieu N (2003) The cancer chemotherapy handbook. Mosby 11:486–497

29.

Blanchard E, Hesketh P (2015) Nausea and vomiting. In: De Vita H, Rosenberg’s (eds) Cancer: principles & practice of oncology, vol 135, 10th edn. Lippincott Williams & Wilkins, pp 1976–1983

30.

Tilignac T, Temparis S, Combaret L, Taillandier D, Pouch MN, Cervek M, Cardenas DM, le Bricon T, Debiton E, Samuels SE, Madelmont JC, Attaix D (2002) Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis. Cancer Res 62:2771–2777PubMed

31.

Prado C (2013) Body composition in chemotherapy: the promising role of CT scans. Curr Opin Clin Nutr Metab Care 16:525–533. https://doi.org/10.1097/MCO.0b013e328363bcfb CrossRefPubMed

Title: Relationship between skeletal muscle function, body composition, and weight loss in patients with advanced pancreatic and gastrointestinal cancers
Authors: P. Cresta Morgado
M. Daud
M. Carballido
G. Méndez
S. Iseas
V. Lobbe
G. De Simone
A. Navigante
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 4/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4421-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer

Unmet supportive care needs in Hispanic/Latino cancer survivors: prevalence and associations with patient-provider communication, satisfaction with cancer care, and symptom burden

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)

Factors associated with the time to first palliative care consultation in Lebanese cancer patients

A qualitative study exploring what it takes to be physically active with a stoma after surgery for rectal cancer

Missed opportunities for physical activity management at key points throughout the chemotherapy pathway for colorectal survivors: an observational interview study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer